Chemotherapy plus targeted therapy for HER2+ early breast cancer
Part of Cancer clinical trials.
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your breast cancer at Peking University People's Hospital
- Your cancer is HER2-positive (a protein that helps cancer grow) and has not spread to lymph nodes
- Your tumor was either 1–2 cm (T1c) with high-risk features, or 2–5 cm (T2) without high-risk features
- You did not receive chemotherapy or other treatment before surgery
- Your cancer is not metastatic (spread to other parts) and is only in one breast
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining chemotherapy with targeted therapy works better for women with high-risk, HER2 positive early breast cancer that hasn't spread to lymph nodes. If you've had surgery and your tumor fits certain high-risk features, you may be eligible to join.
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
This trial tests whether a short course of chemo plus two targeted drugs (trastuzumab and pertuzumab) before surgery works well for people with early-stage, low-risk HER2-positive breast cancer. It may help reduce the need for stronger chemo later.
This study looks at whether using targeted therapy can reduce the amount of chemotherapy needed before surgery for HER2-positive breast cancer. It aims to find a safer, equally effective treatment plan.
This trial looks at the best next treatment for women with HER2-positive breast cancer who still have leftover cancer after surgery and standard pre-surgery treatment. It helps doctors choose the right therapy for you.
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.